![Thomas C. Fisher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas C. Fisher
Plus aucun poste en cours
Profil
Thomas C.
Fisher worked as a Senior Vice President-Operations at Martek Biosciences Corp.
and as a Vice President-Technical Operations at DuPont Merck Pharmaceutical Co. He completed his undergraduate degree at Waynesburg College and his graduate degree at West Virginia University.
Anciens postes connus de Thomas C. Fisher
Sociétés | Poste | Fin |
---|---|---|
DuPont Merck Pharmaceutical Co.
![]() DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
Martek Biosciences Corp.
![]() Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Directeur des opérations | - |
Formation de Thomas C. Fisher
West Virginia University | Graduate Degree |
Waynesburg College | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 2 |
---|---|
Martek Biosciences Corp.
![]() Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Health Technology |
DuPont Merck Pharmaceutical Co.
![]() DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |